25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

ACRS (Aclaris Therapeutics Inc) Stock Analysis
Buy, Hold or Sell?

Let's analyze Aclaris Therapeutics Inc together

I guess you are interested in Aclaris Therapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • πŸ“Š Fundamental Analysis (FA) – Aclaris Therapeutics Inc’s Financial Insights
  • πŸ“ˆ Technical Analysis (TA) – Aclaris Therapeutics Inc’s Price Targets

I'm going to help you getting a better view of Aclaris Therapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Aclaris Therapeutics Inc

I send you an email if I find something interesting about Aclaris Therapeutics Inc.

1. Quick Overview

1.1. Quick analysis of Aclaris Therapeutics Inc (30 sec.)










1.2. What can you expect buying and holding a share of Aclaris Therapeutics Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
2.5%

What is your share worth?

Current worth
$1.18
Expected worth in 1 year
$1.04
How sure are you?
32.5%

+ What do you gain per year?

Total Gains per Share
$-0.13
Return On Investment
-9.3%

For what price can you sell your share?

Current Price per Share
$1.44
Expected price per share
$1.16 - $2.03
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Aclaris Therapeutics Inc (5 min.)




Live pricePrice per Share (EOD)
$1.44
Intrinsic Value Per Share
$-5.62 - $0.04
Total Value Per Share
$-4.45 - $1.22

2.2. Growth of Aclaris Therapeutics Inc (5 min.)




Is Aclaris Therapeutics Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$144m$158.8m-$17.9m-12.7%

How much money is Aclaris Therapeutics Inc making?

Current yearPrevious yearGrowGrow %
Making money-$32.5m-$19.3m-$13.2m-40.7%
Net Profit Margin-664.2%-653.1%--

How much money comes from the company's main activities?

2.3. Financial Health of Aclaris Therapeutics Inc (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  

3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Aclaris Therapeutics Inc?

Welcome investor! Aclaris Therapeutics Inc's management wants to use your money to grow the business. In return you get a share of Aclaris Therapeutics Inc.

First you should know what it really means to hold a share of Aclaris Therapeutics Inc. And how you can make/lose money.

Speculation

The Price per Share of Aclaris Therapeutics Inc is $1.44. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Aclaris Therapeutics Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Aclaris Therapeutics Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $1.18. Based on the TTM, the Book Value Change Per Share is $-0.03 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.08 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Aclaris Therapeutics Inc.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.12-8.6%-0.30-20.6%-0.18-12.4%-0.23-16.1%-0.21-14.3%-0.23-16.0%
Usd Book Value Change Per Share-0.26-18.0%-0.03-2.3%-0.08-5.6%-0.04-2.8%0.032.2%0.032.4%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.26-18.0%-0.03-2.3%-0.08-5.6%-0.04-2.8%0.032.2%0.032.4%
Usd Price Per Share1.53-1.57-4.88-6.61-9.13-11.97-
Price to Earnings Ratio-3.10--2.65--9.22--9.20--12.45--16.61-
Price-to-Total Gains Ratio-5.90--10.95-118.95-19.44--14.90--21.50-
Price to Book Ratio1.30-1.22-3.17-3.77-6.70-9.32-
Price-to-Total Gains Ratio-5.90--10.95-118.95-19.44--14.90--21.50-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share1.44
Number of shares694
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.030.03
Usd Total Gains Per Share-0.030.03
Gains per Quarter (694 shares)-23.3222.21
Gains per Year (694 shares)-93.2988.84
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-93-10308979
20-187-1960178168
30-280-2890266257
40-373-3820355346
50-466-4750444435
60-560-5680533524
70-653-6610622613
80-746-7540710702
90-840-8470799791
100-933-9400888880

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%0.040.00.00.0%0.045.01.00.0%
Book Value Change Per Share1.03.00.025.0%4.08.00.033.3%6.014.00.030.0%13.027.00.032.5%14.028.04.030.4%
Dividend per Share0.00.04.00.0%0.00.012.00.0%1.00.019.05.0%1.00.039.02.5%1.00.045.02.2%
Total Gains per Share1.03.00.025.0%4.08.00.033.3%6.014.00.030.0%13.027.00.032.5%14.028.04.030.4%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Aclaris Therapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.259-0.034-87%-0.080-69%-0.041-84%0.032-911%0.034-858%
Book Value Per Share--1.1771.263-7%1.467-20%1.549-24%1.422-17%1.301-10%
Current Ratio--5.0575.894-14%5.308-5%7.868-36%8.208-38%12.037-58%
Debt To Asset Ratio--0.2730.256+7%0.227+20%0.226+21%0.256+6%0.250+9%
Debt To Equity Ratio--0.3750.349+7%0.297+26%0.297+26%0.368+2%0.291+29%
Dividend Per Share----0%-0%-0%0.000-100%0.000-100%
Enterprise Value--238543163.590239714073.3980%641850077.500-63%837884695.299-72%1100973077.180-78%1474211775.094-84%
Eps---0.123-0.297+141%-0.178+45%-0.232+89%-0.206+68%-0.231+87%
Ev To Ebitda Ratio---3.298-4.571+39%-5.786+75%-9.187+179%-15.450+368%-24.861+654%
Ev To Sales Ratio--40.98719.862+106%55.254-26%64.063-36%129.595-68%177.710-77%
Free Cash Flow Per Share---0.107-0.108+1%-0.170+59%-0.150+40%-0.139+29%-0.142+33%
Free Cash Flow To Equity Per Share---0.1090.064-271%-0.109-1%0.005-2350%0.061-278%0.056-295%
Gross Profit Margin--1.0001.0020%1.862-46%1.288-22%1.174-15%1.153-13%
Intrinsic Value_10Y_max--0.039----------
Intrinsic Value_10Y_min---5.623----------
Intrinsic Value_1Y_max---0.487----------
Intrinsic Value_1Y_min---0.596----------
Intrinsic Value_3Y_max---1.088----------
Intrinsic Value_3Y_min---1.773----------
Intrinsic Value_5Y_max---1.239----------
Intrinsic Value_5Y_min---2.922----------
Market Cap155924640.000-20%187257163.590174856573.398+7%528140577.500-65%717446111.966-74%989197627.180-81%1296175986.340-86%
Net Profit Margin---10.368-6.642-36%-6.531-37%-6.621-36%-8.346-20%-9.573-8%
Operating Margin----2.0960%-7.1040%-5.7800%-7.1640%-7.8990%
Operating Ratio--13.4298.550+57%8.065+67%8.533+57%9.256+45%9.460+42%
Pb Ratio1.223-6%1.3001.218+7%3.165-59%3.773-66%6.702-81%9.317-86%
Pe Ratio-2.921+6%-3.103-2.653-15%-9.219+197%-9.205+197%-12.455+301%-16.608+435%
Price Per Share1.440-6%1.5301.565-2%4.878-69%6.609-77%9.126-83%11.966-87%
Price To Free Cash Flow Ratio-3.363+6%-3.574-1.520-57%-6.629+85%-11.286+216%-17.495+390%-27.674+674%
Price To Total Gains Ratio-5.550+6%-5.897-10.946+86%118.948-105%19.439-130%-14.895+153%-21.501+265%
Quick Ratio--8.3919.652-13%9.938-16%13.610-38%13.810-39%20.196-58%
Return On Assets---0.076-0.156+105%-0.091+20%-0.114+50%-0.117+53%-0.133+75%
Return On Equity---0.105-0.216+107%-0.120+15%-0.153+46%-0.166+59%-0.173+66%
Total Gains Per Share---0.259-0.034-87%-0.080-69%-0.041-84%0.032-911%0.034-858%
Usd Book Value--144066000.000140898250.000+2%158819000.000-9%169074166.667-15%154844650.000-7%141327025.000+2%
Usd Book Value Change Per Share---0.259-0.034-87%-0.080-69%-0.041-84%0.032-911%0.034-858%
Usd Book Value Per Share--1.1771.263-7%1.467-20%1.549-24%1.422-17%1.301-10%
Usd Dividend Per Share----0%-0%-0%0.000-100%0.000-100%
Usd Enterprise Value--238543163.590239714073.3980%641850077.500-63%837884695.299-72%1100973077.180-78%1474211775.094-84%
Usd Eps---0.123-0.297+141%-0.178+45%-0.232+89%-0.206+68%-0.231+87%
Usd Free Cash Flow---13100000.000-12039000.000-8%-18419500.000+41%-16314916.667+25%-15075550.000+15%-15434875.000+18%
Usd Free Cash Flow Per Share---0.107-0.108+1%-0.170+59%-0.150+40%-0.139+29%-0.142+33%
Usd Free Cash Flow To Equity Per Share---0.1090.064-271%-0.109-1%0.005-2350%0.061-278%0.056-295%
Usd Market Cap155924640.000-20%187257163.590174856573.398+7%528140577.500-65%717446111.966-74%989197627.180-81%1296175986.340-86%
Usd Price Per Share1.440-6%1.5301.565-2%4.878-69%6.609-77%9.126-83%11.966-87%
Usd Profit---15085000.000-32552250.000+116%-19315500.000+28%-25422000.000+69%-22441450.000+49%-22326250.000+48%
Usd Revenue--1455000.0004444500.000-67%7779750.000-81%6643666.667-78%4650650.000-69%2979450.000-51%
Usd Total Gains Per Share---0.259-0.034-87%-0.080-69%-0.041-84%0.032-911%0.034-858%
 EOD+3 -5MRQTTM+16 -21YOY+11 -263Y+11 -265Y+12 -2710Y+13 -26

3.3 Fundamental Score

Let's check the fundamental score of Aclaris Therapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-2.921
Price to Book Ratio (EOD)Between0-11.223
Net Profit Margin (MRQ)Greater than0-10.368
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than18.391
Current Ratio (MRQ)Greater than15.057
Debt to Asset Ratio (MRQ)Less than10.273
Debt to Equity Ratio (MRQ)Less than10.375
Return on Equity (MRQ)Greater than0.15-0.105
Return on Assets (MRQ)Greater than0.05-0.076
Total4/10 (40.0%)

3.4 Technical Score

Let's check the technical score of Aclaris Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5049.271
Ma 20Greater thanMa 501.483
Ma 50Greater thanMa 1001.390
Ma 100Greater thanMa 2001.538
OpenGreater thanClose1.460
Total2/5 (40.0%)

4. In-depth Analysis

4.1 About Aclaris Therapeutics Inc

Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. Its Contract Research segment provides laboratory services. The company also develops ATI-1777, a soft JAK 1/3 inhibitor in Phase 2b trial for the treatment of atopic dermatitis and other dermatologic conditions; Bosakitug (ATI-045), an anti-TSLP monoclonal antibody in Phase 2a trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; Zunsemetinib (ATI-450), a mitogen-activated protein kinase-activated protein kinase 2 inhibitor under Phase 1b/2 trials for the treatment of metastatic breast cancer and pancreatic ductal adenocarcinoma; and ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in preclinical stage to treat various atopic, immunologic, and respiratory diseases, as well as an ITK selective inhibitor candidate for the treatment of autoimmune diseases. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

Fundamental data was last updated by Penke on 2025-06-18 22:19:04.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profitΒ Aclaris Therapeutics Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compareΒ Aclaris Therapeutics Inc to theΒ Biotechnology industry mean.
  • A Net Profit Margin of -1,036.8%Β means thatΒ $-10.37 for each $1Β in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Aclaris Therapeutics Inc:

  • The MRQ is -1,036.8%. The company is making a huge loss. -2
  • The TTM is -664.2%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-1,036.8%TTM-664.2%-372.6%
TTM-664.2%YOY-653.1%-11.1%
TTM-664.2%5Y-834.6%+170.4%
5Y-834.6%10Y-957.3%+122.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-1,036.8%-91.7%-945.1%
TTM-664.2%-139.0%-525.2%
YOY-653.1%-194.4%-458.7%
3Y-662.1%-248.5%-413.6%
5Y-834.6%-343.3%-491.3%
10Y-957.3%-488.9%-468.4%
4.3.1.2. Return on Assets

Shows howΒ efficientΒ Aclaris Therapeutics Inc is using its assets to generate profit.

  • Above 5% is considered healthyΒ but always compareΒ Aclaris Therapeutics Inc to theΒ Biotechnology industry mean.
  • -7.6% Return on Assets means thatΒ Aclaris Therapeutics Inc generatedΒ $-0.08 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Aclaris Therapeutics Inc:

  • The MRQ is -7.6%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -15.6%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-7.6%TTM-15.6%+8.0%
TTM-15.6%YOY-9.1%-6.5%
TTM-15.6%5Y-11.7%-3.9%
5Y-11.7%10Y-13.3%+1.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-7.6%-11.6%+4.0%
TTM-15.6%-11.7%-3.9%
YOY-9.1%-11.4%+2.3%
3Y-11.4%-11.9%+0.5%
5Y-11.7%-12.1%+0.4%
10Y-13.3%-13.8%+0.5%
4.3.1.3. Return on Equity

Shows how efficient Aclaris Therapeutics Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compareΒ Aclaris Therapeutics Inc to theΒ Biotechnology industry mean.
  • -10.5% Return on Equity means Aclaris Therapeutics Inc generated $-0.10Β for eachΒ $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Aclaris Therapeutics Inc:

  • The MRQ is -10.5%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -21.6%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-10.5%TTM-21.6%+11.2%
TTM-21.6%YOY-12.0%-9.6%
TTM-21.6%5Y-16.6%-5.0%
5Y-16.6%10Y-17.3%+0.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-10.5%-13.5%+3.0%
TTM-21.6%-15.0%-6.6%
YOY-12.0%-14.5%+2.5%
3Y-15.3%-16.9%+1.6%
5Y-16.6%-17.9%+1.3%
10Y-17.3%-19.9%+2.6%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Aclaris Therapeutics Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

MeasuresΒ how efficient Aclaris Therapeutics Inc is operatingΒ .

  • Measures how much profit Aclaris Therapeutics Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compareΒ Aclaris Therapeutics Inc to theΒ Biotechnology industry mean.
  • An Operating Margin of 0.0%Β means the company generated $0.00 Β for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Aclaris Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-209.6%+209.6%
TTM-209.6%YOY-710.4%+500.8%
TTM-209.6%5Y-716.4%+506.8%
5Y-716.4%10Y-789.9%+73.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--229.2%+229.2%
TTM-209.6%-249.7%+40.1%
YOY-710.4%-208.4%-502.0%
3Y-578.0%-221.7%-356.3%
5Y-716.4%-344.1%-372.3%
10Y-789.9%-470.4%-319.5%
4.3.2.2. Operating Ratio

Measures how efficient Aclaris Therapeutics Inc is keepingΒ operating costsΒ low.

  • Below 1 is considered healthy (always compare toΒ Biotechnology industry mean).
  • An Operation Ratio of 13.43 means that the operating costs are $13.43 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Aclaris Therapeutics Inc:

  • The MRQ is 13.429. The company is inefficient in keeping operating costs low. -1
  • The TTM is 8.550. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ13.429TTM8.550+4.879
TTM8.550YOY8.065+0.484
TTM8.5505Y9.256-0.706
5Y9.25610Y9.460-0.204
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ13.4292.108+11.321
TTM8.5502.680+5.870
YOY8.0653.080+4.985
3Y8.5333.621+4.912
5Y9.2564.734+4.522
10Y9.4606.546+2.914
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Aclaris Therapeutics Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Aclaris Therapeutics Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare toΒ Biotechnology industry mean).
  • A Current Ratio of 5.06Β means the company has $5.06 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Aclaris Therapeutics Inc:

  • The MRQ is 5.057. The company is very able to pay all its short-term debts. +2
  • The TTM is 5.894. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ5.057TTM5.894-0.838
TTM5.894YOY5.308+0.587
TTM5.8945Y8.208-2.313
5Y8.20810Y12.037-3.829
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ5.0573.659+1.398
TTM5.8943.834+2.060
YOY5.3084.141+1.167
3Y7.8684.661+3.207
5Y8.2085.756+2.452
10Y12.0376.151+5.886
4.4.3.2. Quick Ratio

Measures if Aclaris Therapeutics Inc is able to pay off Short-term Debt but only usingΒ theΒ most liquid assets.

  • Above 1 is considered healthy butΒ always compareΒ Aclaris Therapeutics Inc to theΒ Biotechnology industry mean.
  • A Quick Ratio of 8.39Β means the company can pay off $8.39 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Aclaris Therapeutics Inc:

  • The MRQ is 8.391. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 9.652. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ8.391TTM9.652-1.261
TTM9.652YOY9.938-0.286
TTM9.6525Y13.810-4.158
5Y13.81010Y20.196-6.386
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ8.3912.799+5.592
TTM9.6523.143+6.509
YOY9.9383.794+6.144
3Y13.6104.307+9.303
5Y13.8105.707+8.103
10Y20.1966.457+13.739
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Aclaris Therapeutics Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much %Β of Aclaris Therapeutics IncΒ assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compareΒ Aclaris Therapeutics Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.27Β means that Aclaris Therapeutics Inc assets areΒ financed with 27.3% credit (debt) and the remaining percentage (100% - 27.3%)Β is financed by its owners/shareholders.Β 

Let's take a look of the Debt to Asset Ratio trends of Aclaris Therapeutics Inc:

  • The MRQ is 0.273. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.256. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.273TTM0.256+0.017
TTM0.256YOY0.227+0.028
TTM0.2565Y0.256-0.001
5Y0.25610Y0.250+0.006
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2730.324-0.051
TTM0.2560.347-0.091
YOY0.2270.329-0.102
3Y0.2260.340-0.114
5Y0.2560.349-0.093
10Y0.2500.379-0.129
4.5.4.2. Debt to Equity Ratio

Measures ifΒ Aclaris Therapeutics Inc is able toΒ pay off its debts by usingΒ shareholders equity.

  • Below 2 is considered healthy butΒ always compareΒ Aclaris Therapeutics Inc to theΒ Biotechnology industry mean.
  • A Debt to Equity ratio of 37.5% means that company has $0.38 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Aclaris Therapeutics Inc:

  • The MRQ is 0.375. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.349. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.375TTM0.349+0.026
TTM0.349YOY0.297+0.052
TTM0.3495Y0.368-0.018
5Y0.36810Y0.291+0.077
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3750.379-0.004
TTM0.3490.435-0.086
YOY0.2970.412-0.115
3Y0.2970.446-0.149
5Y0.3680.460-0.092
10Y0.2910.509-0.218
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

MeasuresΒ how much money you payΒ for each share forΒ every $1 in earnings Aclaris Therapeutics Inc generates.

  • Above 15 is considered overpriced butΒ always compareΒ Aclaris Therapeutics Inc to theΒ Biotechnology industry mean.
  • A PE ratio of -3.10 means the investor is paying $-3.10Β for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Aclaris Therapeutics Inc:

  • The EOD is -2.921. Based on the earnings, the company is expensive. -2
  • The MRQ is -3.103. Based on the earnings, the company is expensive. -2
  • The TTM is -2.653. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-2.921MRQ-3.103+0.183
MRQ-3.103TTM-2.653-0.450
TTM-2.653YOY-9.219+6.566
TTM-2.6535Y-12.455+9.802
5Y-12.45510Y-16.608+4.153
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-2.921-2.282-0.639
MRQ-3.103-2.062-1.041
TTM-2.653-2.541-0.112
YOY-9.219-3.722-5.497
3Y-9.205-3.754-5.451
5Y-12.455-6.100-6.355
10Y-16.608-6.653-9.955
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Aclaris Therapeutics Inc:

  • The EOD is -3.363. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -3.574. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -1.520. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-3.363MRQ-3.574+0.210
MRQ-3.574TTM-1.520-2.054
TTM-1.520YOY-6.629+5.109
TTM-1.5205Y-17.495+15.975
5Y-17.49510Y-27.674+10.179
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-3.363-3.101-0.262
MRQ-3.574-2.689-0.885
TTM-1.520-3.594+2.074
YOY-6.629-4.363-2.266
3Y-11.286-5.065-6.221
5Y-17.495-8.478-9.017
10Y-27.674-9.273-18.401
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price ofΒ Aclaris Therapeutics Inc is to cheap or to expensiveΒ compared to its book value.

  • At or below 1 is considered healthyΒ (always compare to Biotechnology industry mean).
  • A PB ratio of 1.30 means the investor is paying $1.30Β for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Aclaris Therapeutics Inc:

  • The EOD is 1.223. Based on the equity, the company is underpriced. +1
  • The MRQ is 1.300. Based on the equity, the company is underpriced. +1
  • The TTM is 1.218. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD1.223MRQ1.300-0.076
MRQ1.300TTM1.218+0.082
TTM1.218YOY3.165-1.947
TTM1.2185Y6.702-5.484
5Y6.70210Y9.317-2.615
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD1.2231.932-0.709
MRQ1.3001.848-0.548
TTM1.2182.119-0.901
YOY3.1652.469+0.696
3Y3.7732.526+1.247
5Y6.7023.667+3.035
10Y9.3174.351+4.966
4.6.2. Total Gains per Share

2.4. Latest News of Aclaris Therapeutics Inc

Does Aclaris Therapeutics Inc still have the same value as the quarterly reports suggest? Recent changes may be an indication that the value of the company is changing. Read the news from Aclaris Therapeutics Inc to keep up to date. Note: the news is often already included in the price.

DateTitleRead
2025-06-30
19:01
Aclaris Therapeutics at HCW Conference: Strategic Moves and Future PlansRead
2025-06-26
22:01
Aclaris Therapeutics to Participate in the H.C. WainwrightΒ Inflammation & Immunology Virtual ConferenceRead

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Aclaris Therapeutics Inc.

4.8.1. Institutions holding Aclaris Therapeutics Inc

Institutions are holding 88.26% of the shares of Aclaris Therapeutics Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-03-31BML Capital Management LLC13.160217.64521425000000
2025-03-31Adage Capital Partners Gp LLC8.8910.0273962730400
2025-03-31Vivo Capital, LLC8.20911.8012888888800
2025-03-31Rock Springs Capital Management LP4.66040.44185046309-1158000-18.6644
2025-03-31Vanguard Group Inc4.59010.0001497025464499114.9122
2025-03-31RA Capital Management, LLC4.30980.1192466666700
2025-03-31Millennium Management LLC3.8180.003441341482175101111.0285
2025-03-31Decheng Capital LLC3.73261.73474041736177506978.3119
2024-12-31D. E. Shaw & Co LP3.04170.0063293625-78224-2.3199
2025-03-31Morgan Stanley - Brokerage Accounts2.23080.000324155841343800125.3797
2025-03-31Marshall Wace Asset Management Ltd2.1360.00452312926-321139-12.1918
2025-03-31Logos Global Management LP2.05230.6044222222200
2025-03-31Acadian Asset Management LLC2.02730.00952195191219242679292.0796
2025-03-31Bollard Group LLC1.31530.0572142417614241760
2025-03-31Susquehanna International Group, LLP1.27610.0004138174113026941647.9993
2025-03-31BlackRock Inc1.2569013610371032588.2096
2025-03-31Qube Research & Technologies1.24750.00241350820735737119.6159
2025-03-31Geode Capital Management, LLC1.09230.0001118273739314049.79
2025-03-31Citadel Advisors Llc1.03630.0003112208110667341927.3565
2025-03-31Aldebaran Capital LLC0.93091.45861007958-9000-0.885
Total 71.014623.916676895404+11590763+15.1%

4.9.2. Funds holding Aclaris Therapeutics Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-04-30Vanguard Total Stock Mkt Idx Inv1.97960.00022143511280831.3275
2025-04-30Vanguard Institutional Extnd Mkt Idx Tr1.63960.0024177541200
2025-04-30Xtrackers S&P 500 Swap ETF 1C0.85270.013292331300
2025-03-31Vanguard Strategic Small-Cap Equity Inv0.54720.055759256800
2025-04-30Fidelity Extended Market Index0.54320.0023588208-5623-0.9469
2025-03-31Vanguard VIF Small Co Gr0.26080.0321282349-187874-39.9542
2025-03-31Extended Equity Market Fund K0.21140.00262289389896576.1427
2025-04-30Fidelity Total Market Index0.18910.000320476900
2025-03-31Bridgeway Ultra-Small Company Market0.1820.307719701900
2025-04-30Fidelity Advisor Equity Growth I0.14470.00215664600
2025-04-30Fidelity Series Total Market Index0.1360.0003147260-11899-7.4762
2025-05-31iShares Micro-Cap ETF0.13070.026714157200
2025-04-30Fidelity VIP Growth Initial0.12420.001913450700
2025-03-31Northern Trust Extended Eq Market Idx0.1170.00251266354737059.7616
2025-03-31NT Ext Equity Mkt Idx Fd - L0.1170.00251266354737059.7616
2025-04-30Spartan Extended Market Index Pool F0.11120.002312040156234.899
2025-03-31NT Ext Equity Mkt Idx Fd - NL0.09860.002710675855143106.8352
2025-03-31T. Rowe Price U.S. Equities Tr0.08950.0019690000
2025-04-30Fidelity Growth Discovery0.08180.00228859500
2025-03-31Bridgeway Ultra-Small Company0.07690.16098330000
Total 7.63320.62158265296+77158+0.9%

5.3. Insider Transactions

Insiders are holding 2.689% of the shares of Aclaris Therapeutics Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-11-19Anand MehraBUY6666662.25
2024-07-30Braden Michael LeonardBUY1737301.3
2024-07-22Braden Michael LeonardBUY177161.33
2024-07-18Braden Michael LeonardBUY1303171.3
2024-07-05Braden Michael LeonardBUY1230171.15
2024-07-03Braden Michael LeonardBUY1432881.16
2024-07-01Braden Michael LeonardBUY1074341.14
2024-06-27Braden Michael LeonardBUY2350001.15
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Latest Balance Sheet

Balance Sheet of 2025-03-31. Currency in USD. All numbers in thousands.

Summary
Total Assets198,094
Total Liabilities54,028
Total Stockholder Equity144,066
 As reported
Total Liabilities 54,028
Total Stockholder Equity+ 144,066
Total Assets = 198,094

Assets

Total Assets198,094
Total Current Assets108,790
Long-term Assets89,304
Total Current Assets
Cash And Cash Equivalents 30,357
Short-term Investments 74,957
Net Receivables 250
Other Current Assets 3,226
Total Current Assets  (as reported)108,790
Total Current Assets  (calculated)108,790
+/-0
Long-term Assets
Property Plant Equipment 942
Long Term Investments 85,211
Long-term Assets  (as reported)89,304
Long-term Assets  (calculated)86,153
+/- 3,151

Liabilities & Shareholders' Equity

Total Current Liabilities21,514
Long-term Liabilities32,514
Total Stockholder Equity144,066
Total Current Liabilities
Accounts payable 6,354
Other Current Liabilities 4,918
Total Current Liabilities  (as reported)21,514
Total Current Liabilities  (calculated)11,272
+/- 10,242
Long-term Liabilities
Long-term Liabilities Other 13,308
Long-term Liabilities  (as reported)32,514
Long-term Liabilities  (calculated)13,308
+/- 19,206
Total Stockholder Equity
Common Stock1
Retained Earnings -917,946
Accumulated Other Comprehensive Income 434
Other Stockholders Equity 1,061,577
Total Stockholder Equity (as reported)144,066
Total Stockholder Equity (calculated)144,066
+/-0
Other
Capital Stock1
Cash and Short Term Investments 105,314
Common Stock Shares Outstanding 122,390
Current Deferred Revenue3,888
Liabilities and Stockholders Equity 198,094
Net Debt -30,357
Net Invested Capital 144,066
Net Working Capital 87,276
Property Plant and Equipment Gross 5,856



5.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2025-03-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-31
> Total Assets 
14,207
0
0
0
17,377
0
12,223
42,087
94,076
87,270
96,092
86,071
176,085
166,210
176,808
261,391
243,509
220,622
201,819
176,176
275,566
253,183
217,239
160,416
98,297
96,812
84,999
71,902
70,784
161,399
288,046
263,494
251,211
226,527
277,976
267,632
254,596
229,705
235,649
218,354
197,405
174,065
161,071
182,394
220,327
198,094
198,094220,327182,394161,071174,065197,405218,354235,649229,705254,596267,632277,976226,527251,211263,494288,046161,39970,78471,90284,99996,81298,297160,416217,239253,183275,566176,176201,819220,622243,509261,391176,808166,210176,08586,07196,09287,27094,07642,08712,223017,37700014,207
   > Total Current Assets 
0
13,324
0
0
16,334
16,130
10,444
38,405
92,038
86,833
95,638
85,590
174,134
157,349
175,751
234,122
208,854
192,256
171,172
145,519
179,499
156,813
137,894
145,370
83,803
82,714
70,955
57,997
57,493
134,501
241,261
205,782
205,032
190,881
259,354
256,573
231,550
184,361
132,935
123,068
128,856
135,338
117,635
132,330
125,951
108,790
108,790125,951132,330117,635135,338128,856123,068132,935184,361231,550256,573259,354190,881205,032205,782241,261134,50157,49357,99770,95582,71483,803145,370137,894156,813179,499145,519171,172192,256208,854234,122175,751157,349174,13485,59095,63886,83392,03838,40510,44416,13016,3340013,3240
       Cash And Cash Equivalents 
9,588
-13,324
0
0
10,757
-16,130
9,853
25,419
9,851
13,131
31,815
17,796
30,171
23,677
32,708
60,055
208,854
54,881
46,035
26,590
57,019
34,197
31,654
29,898
35,937
53,992
32,587
23,643
54,131
35,267
113,447
53,602
27,349
36,342
68,264
61,653
45,277
44,722
31,150
39,040
39,878
35,841
22,834
47,651
24,570
30,357
30,35724,57047,65122,83435,84139,87839,04031,15044,72245,27761,65368,26436,34227,34953,602113,44735,26754,13123,64332,58753,99235,93729,89831,65434,19757,01926,59046,03554,881208,85460,05532,70823,67730,17117,79631,81513,1319,85125,4199,853-16,13010,75700-13,3249,588
       Short-term Investments 
3,736
26,648
0
0
5,373
32,260
0
12,986
75,017
72,115
62,195
66,246
107,051
129,741
137,789
167,793
173,655
132,096
118,569
107,681
110,953
102,558
83,863
61,530
39,078
25,013
35,528
29,834
32,068
93,028
118,227
144,280
164,065
143,280
180,339
186,409
172,294
126,081
88,625
64,012
79,228
92,325
88,259
80,071
89,024
74,957
74,95789,02480,07188,25992,32579,22864,01288,625126,081172,294186,409180,339143,280164,065144,280118,22793,02832,06829,83435,52825,01339,07861,53083,863102,558110,953107,681118,569132,096173,655167,793137,789129,741107,05166,24662,19572,11575,01712,986032,2605,3730026,6483,736
       Net Receivables 
0
0
0
0
0
0
0
23
22
20
20
20
20
20
20
658
481
529
2,182
1,033
4,861
15,817
19,370
673
704
933
775
887
772
817
939
811
623
633
637
597
484
686
431
346
298
373
325
343
318
250
25031834332537329834643168648459763763362381193981777288777593370467319,37015,8174,8611,0332,18252948165820202020202022230000000
       Inventory 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-6,364
0
1,026
1,044
791
856
185
51,180
4,966
0
0
0
0
0
0
0
-34,242
0
0
0
-12,242
-33,602
-90,992
-83,944
0
0
0
0
0
0
000000-83,944-90,992-33,602-12,242000-34,24200000004,96651,1801858567911,0441,0260-6,3640000000000000000
   > Long-term Assets 
0
-13,324
0
0
1,043
-16,130
1,779
3,682
2,038
437
454
481
1,951
8,861
1,057
27,269
34,655
28,366
30,647
30,657
96,067
96,370
79,345
15,046
14,494
14,098
14,044
13,905
13,291
26,898
46,785
57,712
46,179
35,646
18,622
11,059
23,046
45,344
102,714
95,286
68,549
38,727
43,436
50,064
94,376
89,304
89,30494,37650,06443,43638,72768,54995,286102,71445,34423,04611,05918,62235,64646,17957,71246,78526,89813,29113,90514,04414,09814,49415,04679,34596,37096,06730,65730,64728,36634,65527,2691,0578,8611,9514814544372,0383,6821,779-16,1301,04300-13,3240
       Property Plant Equipment 
19
0
0
0
515
0
641
761
360
417
434
461
481
706
938
1,203
2,159
2,191
4,375
4,409
4,280
4,026
4,241
2,854
2,470
2,187
2,230
1,920
1,654
1,424
1,287
1,170
1,335
1,277
1,276
1,145
1,099
1,513
1,899
1,764
1,620
5,247
4,396
1,133
1,008
942
9421,0081,1334,3965,2471,6201,7641,8991,5131,0991,1451,2761,2771,3351,1701,2871,4241,6541,9202,2302,1872,4702,8544,2414,0264,2804,4094,3752,1912,1591,203938706481461434417360761641051500019
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
18,504
18,504
18,504
18,504
18,504
18,504
18,504
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000000018,50418,50418,50418,50418,50418,50418,504000000000000000
       Long Term Investments 
0
0
0
0
518
0
0
0
7,170
0
0
0
36,912
0
0
0
14,997
0
0
0
0
0
0
0
0
0
0
0
0
14,362
34,503
45,735
34,242
23,955
7,221
0
12,242
33,602
90,992
83,944
62,771
33,199
38,778
45,714
90,302
85,211
85,21190,30245,71438,77833,19962,77183,94490,99233,60212,24207,22123,95534,24245,73534,50314,36200000000000014,99700036,9120007,1700005180000
       Intangible Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
7,367
7,349
7,330
7,311
7,292
72,951
71,459
69,781
7,217
7,199
7,180
7,161
7,142
7,123
7,105
7,086
7,067
7,048
7,030
7,011
6,992
6,973
6,954
6,935
6,917
269
0
0
0
0
0
000002696,9176,9356,9546,9736,9927,0117,0307,0487,0677,0867,1057,1237,1427,1617,1807,1997,21769,78171,45972,9517,2927,3117,3307,3497,367000000000000000
       Long-term Assets Other 
0
-13,324
0
0
10
-16,130
1,138
2,921
-5,492
20
20
20
-35,442
136
119
195
279
341
457
452
332
2,381
5,323
4,975
4,825
4,731
4,653
4,843
4,514
4,007
3,909
3,740
3,554
3,384
3,114
2,922
-630
3,275
2,888
2,661
1,743
281
262
48,931
3,066
88,362
88,3623,06648,9312622811,7432,6612,8883,275-6302,9223,1143,3843,5543,7403,9094,0074,5144,8434,6534,7314,8254,9755,3232,381332452457341279195119136-35,442202020-5,4922,9211,138-16,1301000-13,3240
> Total Liabilities 
370
0
0
0
38,132
0
1,427
80,205
1,555
4,059
5,852
4,949
6,595
5,921
8,664
17,132
18,247
20,150
27,616
29,848
60,442
70,930
80,009
75,141
28,385
38,637
35,633
31,145
33,134
49,105
54,231
46,913
53,870
46,328
42,224
47,794
56,975
52,895
55,899
62,021
40,226
32,051
27,249
52,243
64,773
54,028
54,02864,77352,24327,24932,05140,22662,02155,89952,89556,97547,79442,22446,32853,87046,91354,23149,10533,13431,14535,63338,63728,38575,14180,00970,93060,44229,84827,61620,15018,24717,1328,6645,9216,5954,9495,8524,0591,55580,2051,427038,132000370
   > Total Current Liabilities 
367
0
0
0
1,451
0
1,424
1,897
1,555
3,729
5,507
4,591
6,223
5,637
8,369
9,993
12,762
13,823
20,069
22,280
27,342
36,228
42,748
38,989
22,432
20,603
17,745
12,788
14,874
14,505
14,916
17,839
22,931
16,726
16,217
19,789
21,938
18,258
22,829
27,320
30,952
20,080
15,682
18,816
31,596
21,514
21,51431,59618,81615,68220,08030,95227,32022,82918,25821,93819,78916,21716,72622,93117,83914,91614,50514,87412,78817,74520,60322,43238,98942,74836,22827,34222,28020,06913,82312,7629,9938,3695,6376,2234,5915,5073,7291,5551,8971,42401,451000367
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
142
142
552
591
142
1,736
1,982
642
637
1,248
1,220
1,182
1,206
1,250
1,294
1,338
1,386
1,432
1,482
1,532
1,368
1,206
916
620
426
503
449
0
0
0
0004495034266209161,2061,3681,5321,4821,4321,3861,3381,2941,2501,2061,1821,2201,2486376421,9821,7361425915521421420000000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
142
142
552
0
0
373
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000000373005521421420000000000000000
       Accounts payable 
353
0
0
0
1,263
0
957
958
810
2,808
3,309
1,774
2,845
3,604
5,848
6,483
7,822
8,055
12,504
13,735
11,675
14,574
14,160
17,780
9,917
6,946
5,502
5,081
5,254
7,292
4,244
7,564
9,985
8,121
5,703
7,667
10,351
8,190
11,425
9,648
8,878
10,810
7,269
7,662
4,690
6,354
6,3544,6907,6627,26910,8108,8789,64811,4258,19010,3517,6675,7038,1219,9857,5644,2447,2925,2545,0815,5026,9469,91717,78014,16014,57411,67513,73512,5048,0557,8226,4835,8483,6042,8451,7743,3092,80881095895701,263000353
       Other Current Liabilities 
14
0
0
0
188
0
467
939
745
921
2,198
2,817
3,378
2,033
2,521
3,510
4,798
5,626
7,013
7,954
15,525
19,918
26,606
14,501
4,157
12,409
11,023
6,525
8,414
5,963
9,378
8,937
11,560
7,173
9,032
10,590
10,219
8,862
10,488
17,052
2,202
9,270
8,413
7,389
23,016
4,918
4,91823,0167,3898,4139,2702,20217,05210,4888,86210,21910,5909,0327,17311,5608,9379,3785,9638,4146,52511,02312,4094,15714,50126,60619,91815,5257,9547,0135,6264,7983,5102,5212,0333,3782,8172,198921745939467018800014
   > Long-term Liabilities 
0
0
0
0
36,681
0
3
78,308
0
330
345
358
372
284
295
7,139
5,485
6,327
7,547
7,568
33,100
34,702
37,261
36,152
5,953
18,034
17,888
18,357
18,260
34,600
39,315
29,074
30,939
29,602
26,007
28,005
35,037
34,637
33,070
34,701
9,274
11,971
11,567
33,427
33,177
32,514
32,51433,17733,42711,56711,9719,27434,70133,07034,63735,03728,00526,00729,60230,93929,07439,31534,60018,26018,35717,88818,0345,95336,15237,26134,70233,1007,5687,5476,3275,4857,139295284372358345330078,3083036,6810000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
29,914
29,918
29,924
30,089
21
10,573
10,573
10,613
10,653
10,692
10,731
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000010,73110,69210,65310,61310,57310,5732130,08929,92429,91829,91400000000000000000000
       Warrants
0
0
0
0
0
0
0
78,305
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000000000000000078,3050000000
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
0
330
345
358
372
284
295
0
4,936
5,778
6,998
7,019
2,637
4,235
6,788
5,673
5,404
6,912
6,766
7,195
7,240
23,541
28,217
28,707
30,572
29,235
25,640
27,638
34,670
34,270
32,703
34,334
9,274
11,971
11,567
12,245
13,139
13,308
13,30813,13912,24511,56711,9719,27434,33432,70334,27034,67027,63825,64029,23530,57228,70728,21723,5417,2407,1956,7666,9125,4045,6736,7884,2352,6377,0196,9985,7784,9360295284372358345330000000000
       Deferred Long Term Liability 
0
0
0
0
4
0
0
0
0
0
0
0
0
0
0
0
549
549
549
549
549
549
0
0
549
549
549
549
367
367
367
367
367
367
367
367
367
367
367
0
0
0
0
0
0
0
0000000367367367367367367367367367367367549549549549005495495495495495490000000000040000
> Total Stockholder Equity
13,837
13,837
0
0
-20,755
15,922
10,796
-38,118
92,521
83,211
90,240
81,122
169,490
160,289
168,144
244,259
225,262
200,472
174,203
146,328
215,124
182,253
137,230
85,275
69,912
58,175
49,366
40,757
37,650
112,294
233,815
216,581
197,341
180,199
235,752
219,838
197,621
176,810
179,750
156,333
157,179
142,014
133,822
130,151
155,554
144,066
144,066155,554130,151133,822142,014157,179156,333179,750176,810197,621219,838235,752180,199197,341216,581233,815112,29437,65040,75749,36658,17569,91285,275137,230182,253215,124146,328174,203200,472225,262244,259168,144160,289169,49081,12290,24083,21192,521-38,11810,79615,922-20,7550013,83713,837
   Common Stock
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1111111111111111000000000000000000000000000000
   Retained Earnings Total Equity0000000-740,044-710,475-682,315-654,680-634,728-614,196-595,407-572,603-551,457-533,296-504,542-491,369-480,710-469,113-453,52700-329,738-292,173-253,622-220,882-189,664-159,435-136,501-118,309-103,471-90,912-79,437-68,743-55,872-42,833-38,1190000000
   Accumulated Other Comprehensive Income 
0
-9,163
0
0
-6
-20,755
-52
1
-149
3
1
-54
-269
-249
-166
-113
-246
-328
-188
-116
-69
-49
8
-1
-66
47
15
-44
-94
-140
-184
-3
-224
-972
-1,326
-1,465
-897
-354
-1,111
-1,129
-106
-364
-463
427
97
434
43497427-463-364-106-1,129-1,111-354-897-1,465-1,326-972-224-3-184-140-94-441547-66-18-49-69-116-188-328-246-113-166-249-269-5413-1491-52-20,755-600-9,1630
   Capital Surplus 
0
0
0
0
0
0
0
0
135,503
139,080
158,982
160,613
260,671
264,009
286,619
380,873
384,943
390,464
395,273
400,066
507,366
512,040
516,836
520,209
523,505
527,241
530,061
532,170
542,286
645,730
785,455
789,186
792,971
795,366
871,805
875,982
880,832
887,638
920,904
0
0
0
0
0
0
0
0000000920,904887,638880,832875,982871,805795,366792,971789,186785,455645,730542,286532,170530,061527,241523,505520,209516,836512,040507,366400,066395,273390,464384,943380,873286,619264,009260,671160,613158,982139,080135,50300000000
   Treasury Stock0000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
0
-36,677
0
38,010
-78,305
135,503
139,080
158,982
160,613
260,671
264,009
286,619
380,873
384,943
390,464
395,273
400,066
507,366
512,040
516,836
520,209
523,505
527,241
530,061
532,170
542,286
645,730
785,455
789,186
792,971
795,366
871,805
875,982
880,832
887,638
920,904
926,766
-70,737,710
930,114
933,007
936,032
1,058,317
1,061,577
1,061,5771,058,317936,032933,007930,114-70,737,710926,766920,904887,638880,832875,982871,805795,366792,971789,186785,455645,730542,286532,170530,061527,241523,505520,209516,836512,040507,366400,066395,273390,464384,943380,873286,619264,009260,671160,613158,982139,080135,503-78,30538,0100-36,6770000



5.3. Balance Sheets

Currency in USD. All numbers in thousands.




5.4. Cash Flows

Currency in USD. All numbers in thousands.




5.5. Income Statements

Currency in USD. All numbers in thousands.


5.6. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue18,720
Cost of Revenue-2,792
Gross Profit3,46215,928
 
Operating Income (+$)
Gross Profit3,462
Operating Expense-157,860
Operating Income-141,932-154,398
 
Operating Expense (+$)
Research Development33,586
Selling General Administrative22,203
Selling And Marketing Expenses0
Operating Expense157,86055,789
 
Net Interest Income (+$)
Interest Income0
Interest Expense-0
Other Finance Cost-0
Net Interest Income0
 
Pretax Income (+$)
Operating Income-141,932
Net Interest Income0
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-132,065-151,799
EBIT - interestExpense = -52,527
-132,065
-132,065
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-52,527-132,065
Earnings Before Interest and Taxes (EBITDA)-51,720
 
After tax Income (+$)
Income Before Tax-132,065
Tax Provision-0
Net Income From Continuing Ops-132,065-132,065
Net Income-132,065
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses160,652
Total Other Income/Expenses Net9,8670
 

Technical Analysis of Aclaris Therapeutics Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Aclaris Therapeutics Inc. The general trend of Aclaris Therapeutics Inc is BEARISH with 42.9% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Aclaris Therapeutics Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-42.9%) Bearish trend (42.9%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Aclaris Therapeutics Inc Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

SupportΒ is a price level at which demand for an asset is strong enough to prevent the price from falling further.
ResistanceΒ is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Aclaris Therapeutics Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 1.655 < 1.775 < 2.03.

The bearish price targets are: 1.3426 > 1.16 > 1.16.

Know someone who trades $ACRS? Share this with them.πŸ‘‡

Aclaris Therapeutics Inc Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows theΒ moving averageΒ of the selected period.

  • Moving averages are laggingΒ trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Aclaris Therapeutics Inc. The current mas is .

The long score for the Moving Averages is 4/14.
The longshort score for the Moving Averages is -6/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Aclaris Therapeutics Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows theΒ momentumΒ of theΒ selected period based on two moving averages.

  • MACD is aΒ lagging momentumΒ indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Aclaris Therapeutics Inc. The current macd is 0.01242752.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Aclaris Therapeutics Inc price going down in the near term. -2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Aclaris Therapeutics Inc. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Aclaris Therapeutics Inc price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Aclaris Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) ChartAclaris Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Aclaris Therapeutics Inc. The current adx is 18.34.

The long score for the Directional Movement Index (DMI) is 1/7.
The longshort score for the Directional Movement Index (DMI) is 1/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Aclaris Therapeutics Inc shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Aclaris Therapeutics Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • ShowsΒ the current trend.
  • ShowsΒ potential entry signals.
  • ShowsΒ Β potential exit signals.
  • Can be used to placeΒ trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Aclaris Therapeutics Inc. The current sar is 1.64411396.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Aclaris Therapeutics Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentumΒ indicator, meaning the signals are instant.
  • RangesΒ between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Aclaris Therapeutics Inc. The current rsi is 49.27. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
Aclaris Therapeutics Inc Daily Relative Strength Index (RSI) ChartAclaris Therapeutics Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

ComparesΒ a certain price to multiple prices ranging over time.

  • LeadingΒ momentumΒ indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • RangesΒ between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Aclaris Therapeutics Inc. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 2/6.
The longshort score for the Stochastic Oscillator is 0/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Aclaris Therapeutics Inc price going up in the near term. +2
  • Trending down: The STOCH %K is trending down. -1
Aclaris Therapeutics Inc Daily Stochastic Oscillator ChartAclaris Therapeutics Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero,Β the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Aclaris Therapeutics Inc. The current cci is -42.62489919.

Aclaris Therapeutics Inc Daily Commodity Channel Index (CCI) ChartAclaris Therapeutics Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Aclaris Therapeutics Inc. The current cmo is -5.36942831.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Aclaris Therapeutics Inc Daily Chande Momentum Oscillator (CMO) ChartAclaris Therapeutics Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

Β Shows the current price relative to the highest high over the last 14 days.
Β 

  • Lagging momentum indicator
  • Ranging between 0 andΒ -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Aclaris Therapeutics Inc. The current willr is -68.82202305.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Aclaris Therapeutics Inc is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Aclaris Therapeutics Inc Daily Williams %R ChartAclaris Therapeutics Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversoldΒ 

Score

Let's take a look at the Bollinger Bands of Aclaris Therapeutics Inc.

Aclaris Therapeutics Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Aclaris Therapeutics Inc. The current atr is 0.1032455.

Aclaris Therapeutics Inc Daily Average True Range (ATR) ChartAclaris Therapeutics Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

Β Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Aclaris Therapeutics Inc. The current obv is 18,100,826.

Aclaris Therapeutics Inc Daily On-Balance Volume (OBV) ChartAclaris Therapeutics Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Aclaris Therapeutics Inc. The current mfi is 16.96.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -2/(-2 +2).

  • MFI < 50: -1
  • MFI < 20: -1
Aclaris Therapeutics Inc Daily Money Flow Index (MFI) ChartAclaris Therapeutics Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Aclaris Therapeutics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-02-11SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-02-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-02-13STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-19MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-20STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-21STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-24MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-02-26STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-27STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-02-28STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-04STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-05WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-07STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-10STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-13MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-03-14STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-18MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-03-19STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-20SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-21MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-03-24RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2025-03-26STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-27STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-31SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-04-01WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-04-02RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-03STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-04-04CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-04-07STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-08MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-09STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-10STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-11STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-15STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-04-17STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-22MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-23RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-24SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-04-28DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-04-29STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-30STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-02CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-05-05STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-05-06DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-05-08DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-05-09STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-13WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-05-14DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2025-05-15STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-16DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-05-20SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-05-21STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-22CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-23STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-28CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-05-29BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-06-02STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-03STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-04WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-06-05STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-06-11WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-06-12STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-16MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-06-17WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-06-20STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-06-23DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-06-24DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-25MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-26STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-27MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-06-30DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2025-07-01SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-07-02DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

Aclaris Therapeutics Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Aclaris Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5049.271
Ma 20Greater thanMa 501.483
Ma 50Greater thanMa 1001.390
Ma 100Greater thanMa 2001.538
OpenGreater thanClose1.460
Total2/5 (40.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Aclaris Therapeutics Inc with someone you think should read this too:
  • Are you bullish or bearish on Aclaris Therapeutics Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Aclaris Therapeutics Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Aclaris Therapeutics Inc

I send you an email if I find something interesting about Aclaris Therapeutics Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Aclaris Therapeutics Inc.

Receive notifications about Aclaris Therapeutics Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.